A recent article published on the website The Hill discusses the problem of prescribing addictive schedule III drugs for pain relief rather than the equally effective and non-addictive schedule II drugs.
News
The latest news and views from bridge therapeutics
As President Trump promises to fight the opioid epidemic, here are 14 things experts want him to know Greg Sullivan, MD, Chief Scientific Officer & CEO of Bridge Therapeutics, recently spoke with Managed Healthcare Executive for a special report entitled, “Fourteen things Trump needs to know about opioids.” Managed Healthcare Executive is read by 40,000…
CEO Dr. Greg Sullivan to introduce Bridge and its investigational drug BT-205 to investors and industry executives (PRNewswire) — Bridge Therapeutics, Inc., an innovative development-stage specialty pharmaceutical company, announced that its CEO and Chief Scientific Officer Greg Sullivan, MD, presented at BioTrinity 2017 in London on Thursday, May 11. BioTrinity is Europe’s leading biopartnering and investment conference…